论文部分内容阅读
目的探究紫杉醇静脉联合顺铂腹腔给药治疗晚期卵巢癌的疗效和安全性。方法病例选取我院2011年4月~2015年4月收治的62例晚期卵巢癌患者,利用随机数表法分为两组。观察组31人,采用腹腔给药法。对照组31人,采用静脉滴注给药法。治疗后比较两组患者疗效和毒副作用情况。结果观察组治疗总有效率(93.55%)明显大于对照组(70.97%)(P<0.0 5)。观察组不良反应率(48.39%)与对照组(51.61%)差异无统计学意义(P>0.05)。结论紫杉醇静脉联合顺铂腹腔给药治疗晚期卵巢癌具有很好的临床疗效,安全性高,值得临床推广。
Objective To investigate the efficacy and safety of intravenous paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer. Methods Sixty-two patients with advanced ovarian cancer who were treated in our hospital from April 2011 to April 2015 were selected and randomized into two groups. Observation group of 31 people, using intraperitoneal administration. Control group of 31 people, using intravenous drip method. After treatment, the curative effect and side effect of the two groups were compared. Results The total effective rate (93.55%) in observation group was significantly higher than that in control group (70.97%) (P <0.05). There was no significant difference between the observation group (48.39%) and the control group (51.61%) (P> 0.05). Conclusion Intraperitoneal administration of paclitaxel plus cisplatin in the treatment of advanced ovarian cancer has good clinical efficacy, high safety and is worthy of clinical promotion.